Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HBM9161 in active moderate-to-severe thyroid eye disease
ChiCTR2100050401Phase 2Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of batoclimab in Graves Orbitopathy (GO) (3 arms), sponsored by Shanghai Ninth People's Hospital. Primary endpoint: Exophthalmos response rate. Planned start Sep 2021; status: not yet recruiting.
02
Drugs
batoclimab
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on ChiCTR2100050401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050401.